References
- Pizzo PA, Poplack DG. Principles and Practice of Pediatric Oncology. 6th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2011.
- van der Graaf WT, Orbach D, Judson IR, Ferrari A. Soft tissue sarcomas in adolescents and young adults: A comparison with their paediatric and adult counterparts. Lancet Oncol 2017;18:e166-75.
- Gatta G, Botta L, Rossi S, Aareleid T, Bielska-Lasota M, Clavel J, et al. Childhood cancer survival in Europe 1999-2007: Results of EUROCARE-5-a population-based study. Lancet Oncol 2014;15:35-47.
- Meza JL, Anderson J, Pappo AS, Meyer WH, Children’s Oncology Group. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on Intergroup Rhabdomyosarcoma Studies III and IV: The children’s oncology group. J Clin Oncol 2006;24:3844-51.
- Stevens MC, Rey A, Bouvet N, Ellershaw C, Flamant F, Habrand JL, et al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: Third study of the international society of paediatric oncology-SIOP malignant mesenchymal tumour 89. J Clin Oncol 2005;23:2618-28.
- Thavaraj V, Kumar R, Dawar R, Gupta DK, Mohanti BK, Singh R, et al. Treatment outcome and survival of rhabdomyosarcoma (RMS) in children. Med Pediatr Oncol 2001;37:286.
- Dua V, Yadav SP, Prakash A, Sachdeva A. Encouraging treatment outcomes of pediatric rhabdomyosarcoma: A developing world experience. Pediatr Hematol Oncol 2012;29:677-8.
- Bhurgri Y, Bhurgri A, Puri R, Ashraf S, Qidwai A, Ashraf K, et al. Rhabdomyosarcoma in Karachi 1998-2002. Asian Pac J Cancer Prev 2004; 5:284-90.
- Antillon F, Castellanos M, Valverde P, Luna-Fineman S, Garrido C, Serrato T, et al. Treating pediatric soft tissue sarcomas in a country with limited resources: The experience of the Unidad Nacional de oncologia pediatrica in guatemala. Pediatr Blood Cancer 2008;51:760-4.
- Raney RB, Maurer HM, Anderson JR, Andrassy RJ, Donaldson SS, Qualman SJ, et al. The intergroup rhabdomyosarcoma study group (IRSG): Major lessons from the IRS-I through IRS-IV studies as background for the current IRS-V treatment protocols. Sarcoma 2001;5:9-15.
- Lawrence W Jr., Anderson JR, Gehan EA, Maurer H. Pretreatment TNM staging of childhood rhabdomyosarcoma: A report of the intergroup rhabdomyosarcoma study group. Children’s cancer study group. Pediatric oncology group. Cancer 1997;80:1165-70.
- Rudzinski ER, Kelsey A, Vokuhl C, Linardic CM, Shipley J, Hettmer S, et al. Pathology of childhood rhabdomyosarcoma: A consensus opinion document from the Children’s oncology group, European paediatric soft tissue sarcoma study group, and the cooperative weichteilsarkom studiengruppe. Pediatr Blood Cancer 2021;68:e28798.
- Dagher R, Helman L. Rhabdomyosarcoma: An overview. Oncologist 1999;4:34-44.
- Sultan I, Qaddoumi I, Yaser S, Rodriguez-Galindo C, Ferrari A. Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: An analysis of 2, 600 patients. J Clin Oncol 2009;27:3391-7.
- Malempati S, Hawkins DS. Rhabdomyosarcoma: Review of the children’s oncology group (COG) soft- tissue sarcoma committee experience and rationale for current COG studies. Pediatr Blood Cancer 2012;59:5-10.
- Walterhouse DO, Pappo AS, Meza JL, Breneman JC, Hayes-Jordan AA, Parham DM, et al. Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: A report from the soft tissue sarcoma committee of the children’s oncology group. J Clin Oncol 2014;32:3547-52.
- Hawkins DS, Anderson JR, Mascarenhas L, McCowage GB, Rodeberg DA, Wolden SL, et al. Vincristine, dactinomycin, cyclophosphamide (VAC) versus VAC/V plus irinotecan (VI) for intermediate-risk rhabdomyosarcoma (IRRMS): A report from the children’s oncology group soft tissue sarcoma committee. ASCO Meet Abs 2014;32 Suppl 15:10004.
- Weigel BJ, Lyden E, Anderson JR, Meyer WH, Parham DM, Rodeberg DA, et al. Intensive multiagent therapy, including dose-compressed cycles of ifosfamide/etoposide and vincristine/doxorubicin/ cyclophosphamide, irinotecan, and radiation in patients with high-risk rhabdomyosarcoma: A report from the children’s oncology group. J Clin Oncol 2016;34:117-22.
- Qureshi BM, Rizvi A. Prognostic factors and their influence on therapeutic outcomes in children and adolescents with parameningeal rhabdomyosarcoma: A multicenter study from Pakistan. Pediatr Hematol Oncol J 2021;6:6-11.
- Arora RS, Eden T, Pizer B. The problem of treatment abandonment in children from developing countries with cancer. Pediatr Blood Cancer 2007;49:941-6.
- Rudzinski ER, Anderson JR, Chi YY, Gastier-Foster JM, Astbury C, Barr FG, et al. Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the children’s oncology group. Pediatr Blood Cancer 2017;64:e26645.